Beijing’s answer is clear and restrictive: tech founders can be barred from leaving China during acquisition negotiations, particularly when geopolitical concerns or national security reviews are involved. The precedent was set in 2026 when China’s regulators blocked Meta’s $2 billion acquisition of Manus AI and simultaneously prevented the startup’s two founders—CEO Xiao Hong and Chief Scientist Ji Yichao—from leaving the country during the review process. While the founders could travel within China’s borders, they were unable to depart for international meetings, investor calls, or strategic discussions that might normally accompany a negotiation of this scale. This represents a fundamental shift in how Beijing manages cross-border tech deals and signals that founders cannot assume freedom of movement once regulators begin scrutinizing an acquisition.
The restriction placed on Manus’s founders was not arbitrary. In March 2026, both founders were summoned to Beijing for meetings with officials from the National Development and Reform Commission. After those meetings concluded, they were informally barred from international travel—a form of regulatory control that falls short of formal detention but carries unmistakable consequences. The founders could conduct business within China, but negotiating with Meta’s international teams, visiting Silicon Valley for due diligence, or attending board meetings overseas became impossible. This constraint effectively gave Chinese regulators leverage over the deal’s progression and signaled that founders remain under Beijing’s jurisdiction regardless of whether their company maintains offshore structures.
Table of Contents
- Why Does Beijing Restrict Founder Movement During Foreign Acquisitions?
- The Manus Deal: Inside the Case That Changed Everything
- Singapore-Washing and the Myth of Offshore Protection
- What Does “Cannot Leave China” Actually Mean in Practice?
- The Geopolitical Lens Now Applied to All Tech Acquisitions
- How the Restrictions Affect Deal Timelines and Strategy
- The Future of Cross-Border Tech M&A Between China and Western Companies
- Conclusion
Why Does Beijing Restrict Founder Movement During Foreign Acquisitions?
China’s regulatory framework treats cross-border acquisitions involving technology, artificial intelligence, and innovation-critical talent as matters of national strategic importance. When a foreign acquirer seeks to buy a Chinese tech startup, Beijing’s perspective is that valuable intellectual property, research capabilities, and technical expertise are leaving the country. By controlling whether founders can travel internationally, regulators gain negotiating power and can prevent founders from making unilateral commitments that might contradict China’s interests. The Manus case was particularly sensitive because Meta was acquiring an AI startup during a period of escalating U.S.-China competition in artificial intelligence—a domain Beijing considers essential to national competitiveness.
The regulatory review process introduced in late 2020 gave China formal authority to block foreign acquisitions on national security grounds, but controlling founder movement goes beyond formal review procedures. It operates as a soft constraint that keeps founders psychologically and practically tethered to China during critical negotiation periods. Founders cannot easily fly to meet their potential acquirer’s board, cannot attend investor presentations in other countries, and cannot consult with international advisors without explicit permission. This asymmetry of control—where regulators can summon founders but founders cannot freely leave—creates an environment where Beijing effectively shapes the negotiation’s trajectory by controlling the mobility of one party.
The Manus Deal: Inside the Case That Changed Everything
The Manus AI acquisition offer from Meta came with a headline $2 billion valuation in December 2025, but the deal faced scrutiny from the moment it was announced. Meta, facing reputational challenges and regulatory pressure in multiple jurisdictions, saw Manus’s AI research capabilities as a way to strengthen its artificial intelligence division. For Chinese regulators, however, the deal represented exactly the kind of capital flight and technology transfer they had warned against in their 2020 foreign investment security review framework. In March 2026, CEO Xiao Hong and Chief Scientist Ji Yichao were called to Beijing for meetings with the National Development and Reform Commission to discuss the transaction. Those meetings marked the point of no return.
After the officials concluded their discussions with the founders, both men were effectively prohibited from leaving China. The restriction was not formalized as a travel ban or exit restriction—there was no public announcement or official document—but it operated as an understood constraint. Founders were informed they could remain in China, conduct meetings domestically, and continue their business operations, but international travel would not be approved during the regulatory review period. On April 27-28, 2026, regulators voided the entire Meta-Manus deal, citing national security concerns. By that point, the founders’ inability to travel had already constrained the negotiation process for weeks. The blockage of the deal itself sent a signal far beyond Meta and Manus: foreign companies cannot acquire cutting-edge Chinese AI startups without explicit, advance approval from Beijing.
Singapore-Washing and the Myth of Offshore Protection
For years, a common strategy among Chinese tech entrepreneurs was “Singapore-washing”—registering the company offshore, relocating the founder to Singapore or another Southeast Asian hub, and attempting to operate outside Beijing’s regulatory jurisdiction while maintaining the company’s technical team and intellectual property in China. This strategy worked for many startups during the 2010s and early 2020s because the regulatory boundaries were murky. If the founder wasn’t physically in mainland China and the company was nominally registered abroad, there was an assumption that Chinese regulators had limited authority. That assumption no longer holds. Beijing’s current position is explicit: shifting corporate registration offshore does not place a company beyond regulatory reach if the founders, the technology, the research team, or core intellectual property remain tied to mainland China.
This means a founder living in Singapore while managing a research team in Beijing, or maintaining company operations across both countries, will still be subject to Chinese regulatory control during sensitive acquisitions. The implication is profound. The traditional playbook of going offshore to escape Beijing’s oversight no longer works as a reliable protection during foreign acquisitions. A founder cannot relocate to Singapore, maintain their Chinese research team, and then expect freedom of movement when a foreign buyer comes calling. Beijing will simply summon the founder back and assert regulatory authority over the deal regardless of corporate domicile.
What Does “Cannot Leave China” Actually Mean in Practice?
The travel restriction imposed on the Manus founders was not a formal legal prohibition announced through official channels. Instead, it operated as an informal constraint—founders were not physically prevented from boarding planes, but they understood that attempting international departure would result in regulatory consequences. This distinction matters because it blurs the line between formal legal restrictions and practical control. For founders facing this situation, the uncertainty itself becomes a constraint. Does “cannot leave” mean border security will physically prevent departure, or does it mean the regulatory environment will deteriorate further if they attempt to leave? Founders typically err on the side of caution.
In the Manus case, the founders remained in China for the duration of the regulatory review, conducting video calls with Meta’s negotiating team and with their own board members who were located internationally. However, the inability to travel meant they could not handle critical in-person negotiations, could not visit Meta’s offices for strategic discussions, and could not attend shareholder meetings if required. Acquisitions of this scale typically involve multiple rounds of face-to-face meetings, technical due diligence conducted on-site, and in-person negotiations that cannot be replicated over video. By keeping founders in China, regulators effectively slowed the deal’s progression and limited the founders’ ability to advocate for it during critical moments. The practical impact was a severe constraint on the negotiation process without any formal legal action.
The Geopolitical Lens Now Applied to All Tech Acquisitions
China’s blocking of the Meta-Manus deal was the first use of the foreign investment security review framework to formally reject a major cross-border technology acquisition, but it was not surprising given the geopolitical context. U.S.-China competition in artificial intelligence is viewed by Beijing as an existential strategic issue. Allowing Meta, a U.S. technology giant, to acquire advanced AI research capabilities housed in China would directly undermine China’s competitive position in a domain Beijing considers essential to future power. This reasoning extends beyond Meta. Any cross-border M&A involving Chinese talent, intellectual property, or technology capabilities that touch artificial intelligence, semiconductors, biotechnology, or other strategic domains is now evaluated through a geopolitical lens.
The “regulatory discount” applied to future cross-border tech deals has become quantifiable. Venture capital investors and acquiring companies now factor in the assumption that Chinese regulatory approval is uncertain, deals may face long review periods, and founders may experience restrictions on their mobility. This uncertainty depresses valuations for Chinese startups that might have otherwise attracted foreign acquisitions. A Chinese AI startup that might have commanded a $2 billion offer in 2024 may now receive a $1.2 billion offer in 2026 because the buyer must account for the risk that Beijing will block the deal mid-negotiation. The hidden cost is borne by founders and early investors who face lower exit valuations due to geopolitical risk. Additionally, founders should be aware that the regulatory review process may not be transparent. Officials may not clearly communicate timeline expectations or approval likelihood, leaving founders in extended periods of uncertainty.
How the Restrictions Affect Deal Timelines and Strategy
For founders currently in acquisition negotiations with foreign buyers, the travel restrictions mean that deal timelines cannot be rushed. A founder who receives a letter indicating that international travel may be restricted during regulatory review should expect the negotiation period to extend significantly beyond what would normally be anticipated. In traditional M&A, a complex acquisition might require four to six months of negotiation and due diligence. For deals involving Chinese startups and foreign acquirers in strategic sectors, founders should now anticipate potentially nine to twelve months or longer, during which mobility may be constrained. This creates a strategic dilemma for founders.
One approach is to proactively seek regulatory approval before the deal is public or before it reaches advanced negotiation stages. Founders can informally consult with relevant Chinese ministries about whether a particular acquisition might face regulatory hurdles. However, this approach risks alerting regulators to the deal earlier than the founder might have preferred. An alternative approach is to structure the deal in ways that Beijing might view as less threatening—perhaps by agreeing to maintain research operations in China, committing to Chinese market reinvestment, or structuring the deal so that ownership changes but operational control remains distributed. Neither approach guarantees approval, but both attempt to anticipate Beijing’s likely concerns. The Manus founders likely wish they had anticipated these constraints earlier in the negotiation process.
The Future of Cross-Border Tech M&A Between China and Western Companies
The Meta-Manus case suggests that cross-border M&A in strategic technology sectors will become increasingly difficult between China and Western acquirers. Beijing is unlikely to relax its review standards given the ongoing geopolitical competition. If anything, the criteria for “national security risk” may expand rather than narrow. Startups in artificial intelligence, semiconductors, biotechnology, quantum computing, and other strategic domains should assume that foreign acquisition attempts will face regulatory scrutiny and that founder mobility may be constrained during review periods. The practical consequence is that Chinese startups with strategic technology may find their primary acquisition path blocked unless the acquirer is also Chinese.
This could accelerate the trend of Chinese founders prioritizing domestic Chinese acquirers or seeking exits through domestic venture capital rather than Western strategic buyers. Looking forward, founders and investors will likely shift strategies. Some Chinese startups may avoid foreign acquirer interest altogether, positioning themselves exclusively for domestic acquisition. Others may move earlier in their lifecycle to seek international acquisition at seed or Series A stages, before the technology becomes sensitive. Still others may attempt to build operational presence outside China to create genuine regulatory separation—though Beijing’s evolving position suggests this will become harder to achieve. The Manus case has set a precedent that Beijing will use founder mobility as a control mechanism during regulatory review, and future founders must factor that precedent into their acquisition strategy.
Conclusion
Beijing’s answer to whether tech founders can cross borders during acquisition negotiations is: only with explicit regulatory approval, and often not at all during sensitive reviews. The Manus AI case established a new precedent where founders can be prevented from leaving China while regulators evaluate a foreign acquisition, effectively constraining the negotiation process and giving Beijing leverage over the deal’s outcome. For any founder considering a foreign acquisition of a Chinese tech startup, particularly in strategic sectors like artificial intelligence, it is essential to anticipate regulatory review, understand that travel restrictions may be imposed, and plan negotiation timelines accordingly. The days of offshore incorporation providing automatic protection from Beijing’s regulatory reach are over.
Founders must approach cross-border acquisitions with the assumption that they may be constrained to China during critical review periods, and that Beijing will prioritize national security concerns over transaction timelines or founder convenience. The future of cross-border tech M&A between China and Western companies will likely become more constrained, not less. Founders and investors should adjust valuations, timelines, and strategic expectations accordingly. If you are currently in acquisition discussions with a foreign buyer, consulting quietly with relevant Chinese regulators about approval likelihood—without triggering premature regulatory intervention—may be one of the few strategic moves available.